192 related articles for article (PubMed ID: 33938701)
1. Vismodegib as Eye-Sparing Neoadjuvant Treatment for Locally Advanced Periocular Basal Cell Carcinoma.
Angnardo L; Humeda Y; Alexandraki I; Wolfe CM; Cognetta AB
J Drugs Dermatol; 2021 May; 20(5):552-554. PubMed ID: 33938701
[TBL] [Abstract][Full Text] [Related]
2. Ocular preservation with neoadjuvant vismodegib in patients with locally advanced periocular basal cell carcinoma.
Sagiv O; Nagarajan P; Ferrarotto R; Kandl TJ; Thakar SD; Glisson BS; Altan M; Esmaeli B
Br J Ophthalmol; 2019 Jun; 103(6):775-780. PubMed ID: 30021814
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Vismodegib and Mohs Micrographic Surgery for Locally Advanced Periocular Basal Cell Carcinoma.
González AR; Etchichury D; Gil ME; Del Aguila R
Ophthalmic Plast Reconstr Surg; 2019; 35(1):56-61. PubMed ID: 30444747
[TBL] [Abstract][Full Text] [Related]
4. Impact of Food and Drug Administration Approval of Vismodegib on Prevalence of Orbital Exenteration as a Necessary Surgical Treatment for Locally Advanced Periocular Basal Cell Carcinoma.
Sagiv O; Ding S; Ferrarotto R; Glisson B; Altan M; Johnson F; Elamin Y; Thakar SD; Nagarajan P; Esmaeli B
Ophthalmic Plast Reconstr Surg; 2019; 35(4):350-353. PubMed ID: 30365473
[TBL] [Abstract][Full Text] [Related]
5. Vismodegib for periocular and orbital basal cell carcinoma.
Gill HS; Moscato EE; Chang AL; Soon S; Silkiss RZ
JAMA Ophthalmol; 2013 Dec; 131(12):1591-4. PubMed ID: 24136169
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase II study evaluating vismodegib as neoadjuvant treatment of basal cell carcinoma preceding Mohs micrographic surgery: results and lessons learned.
Soon SL; Ibrahim SF; Arron ST
Br J Dermatol; 2019 Jul; 181(1):208-209. PubMed ID: 30628055
[No Abstract] [Full Text] [Related]
7. Vismodegib as a neoadjuvant treatment to Mohs surgery for aggressive basal cell carcinoma.
Alcalay J; Tauber G; Fenig E; Hodak E
J Drugs Dermatol; 2015 Mar; 14(3):219-23. PubMed ID: 25738842
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Vismodegib (Erivedge) for Basal Cell Carcinoma Involving the Orbit and Periocular Area.
Demirci H; Worden F; Nelson CC; Elner VM; Kahana A
Ophthalmic Plast Reconstr Surg; 2015; 31(6):463-6. PubMed ID: 25675162
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of Vismodegib for Periocular Locally Advanced Basal Cell Carcinoma From an Open-label Trial.
Ben Ishai M; Tiosano A; Fenig E; Ben Simon G; Yassur I
JAMA Ophthalmol; 2020 Jul; 138(7):749-755. PubMed ID: 32407451
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant vismodegib in the management of locally advanced periocular basal cell carcinoma.
Curragh DS; Huilgol SC; Selva D
Eye (Lond); 2021 Oct; 35(10):2740-2745. PubMed ID: 33235336
[TBL] [Abstract][Full Text] [Related]
11. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
12. Secondary Resistance to Vismodegib After Initial Successful Treatment of Extensive Recurrent Periocular Basal Cell Carcinoma with Orbital Invasion.
Papastefanou VP; René C
Ophthalmic Plast Reconstr Surg; 2017; 33(3S Suppl 1):S68-S70. PubMed ID: 26398246
[TBL] [Abstract][Full Text] [Related]
13. Management of periorbital basal cell carcinoma with orbital invasion.
Sun MT; Wu A; Figueira E; Huilgol S; Selva D
Future Oncol; 2015 Nov; 11(22):3003-10. PubMed ID: 26437207
[TBL] [Abstract][Full Text] [Related]
14. Oral Hedgehog Pathway Inhibition as a Means for Ocular Salvage in Locally Advanced Intraorbital Basal Cell Carcinoma.
Mathis J; Doerr T; Lin E; Ibrahim SF
Dermatol Surg; 2019 Jan; 45(1):17-25. PubMed ID: 30586344
[TBL] [Abstract][Full Text] [Related]
15. Two different scenarios of advanced basal cell carcinomas during the use of vismodegib: Cases of oral administration and administration directly to the stomach.
Rodríguez-Cerdeira C; Muñoz-Garzón V; González-Cespón JL
Drug Discov Ther; 2019; 13(2):122-127. PubMed ID: 31080204
[TBL] [Abstract][Full Text] [Related]
16. Concurrent Vismodegib and Radiotherapy for Recurrent, Advanced Basal Cell Carcinoma.
Pollom EL; Bui TT; Chang AL; Colevas AD; Hara WY
JAMA Dermatol; 2015 Sep; 151(9):998-1001. PubMed ID: 25874733
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Vismodegib for the Treatment of Orbital and Advanced Periocular Basal Cell Carcinoma.
Eiger-Moscovich M; Reich E; Tauber G; Berliner O; Priel A; Ben Simon G; Elkader AA; Yassur I
Am J Ophthalmol; 2019 Nov; 207():62-70. PubMed ID: 31077664
[TBL] [Abstract][Full Text] [Related]
18. Identifying patients at risk for recurrent or advanced BCC.
Hamid O; Goldenberg G
J Drugs Dermatol; 2013 Nov; 12(11):1246-52; quiz 1253-4. PubMed ID: 24196332
[TBL] [Abstract][Full Text] [Related]
19. A Review of Hedgehog Inhibitors Sonidegib and Vismodegib for Treatment of Advanced Basal Cell Carcinoma.
Migden M; Farberg AS; Dummer R; Squittieri N; Hanke CW
J Drugs Dermatol; 2021 Feb; 20(2):156-165. PubMed ID: 33538567
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, rate of tumor response, and safety of a short course (12-24 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular, and superficial) of high-risk or locally advanced basal cell carcinoma, in an open-label, prospective case series clinical trial.
Fosko SW; Chu MB; Armbrecht E; Galperin T; Potts GA; Mattox A; Kurta A; Polito K; Slutsky JB; Burkemper NM; Hurley MY
J Am Acad Dermatol; 2020 Apr; 82(4):946-954. PubMed ID: 31836564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]